Clinical Trials | April 22, 2026
Asahi Kasei pushes into human trials with new autoimmune drug candidate
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
By cutting pain crises & boosting haemoglobin
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
Subscribe To Our Newsletter & Stay Updated
